Glen Kristiansen

Are you Glen Kristiansen?

Claim your profile

Publications (2)2.07 Total impact

  • Article: Prognostic value of immunohistochemical estimation of CD24 and Ki67 expression in cisplatin and paclitaxel treated ovarian carcinoma patients.
    Paweł Surowiak, Verena Materna, Katarzyna Kłak, Marek Spaczyński, Manfred Dietel, Glen Kristiansen, Hermann Lage, Maciej Zabel
    [show abstract] [hide abstract]
    ABSTRACT: CD24 is a small membranous protein which may participate in invasion of tumor cells. Present study aimed at evaluation of prognostic significance linked to immunohistochemical demonstration of CD24 expression and the proliferation index, Ki67 expression in ovarian cancers. The immunohistochemical reactions with monoclonal CD24- and Ki67-specific antibodies were performed in paraffin sections originating from 30 patients with ovarian cancer treated using cisplatin and paclitaxel. Results of the reactions and analysis of the clinical course of the patients were subjected to statistical analysis. Cases with cytoplasmic-membranous expression of CD24 (CD24c-m) were found to exhibit significantly shorter overall survival time (P = 0.0002) and progression-free period (P = 0.0005). Cases with membranous expression of CD24 (CD24m) manifested a longer overall survival time (P = 0.022). No relationship was disclosed between expression of Ki67 on the one hand and survival time and CD24 expression on the other. As documented using chi square test, expression of CD24c-m predisposed to relapses (P = 0.012), progression (P = 0.0362) and to death (P = 0.0034). Deaths were encountered significantly less frequently in cases with CD24m expression (P = 0.0465). The studies demonstrated that CD24c-m represented a strongly unfavorable prognostic indicator. The antigen represents an interesting target in the search for novel therapeutic methods. The more aggressive course of cases with CD24c-m expression was not linked to more intense proliferation of the tumor cells.
    Polish journal of pathology: official journal of the Polish Society of Pathologists 02/2005; 56(2):69-74. · 0.35 Impact Factor
  • Source
    Article: CD24 expression is specific for tamoxifen-resistant ductal breast cancer cases.
    Pawel Surowiak, Verena Materna, Piotr Paluchowski, Rafal Matkowski, Andrzej Wojnar, Adam Maciejczyk, Marek Pudelko, Jan Kornafel, Manfred Dietel, Glen Kristiansen, Hermann Lage, Maciej Zabel
    [show abstract] [hide abstract]
    ABSTRACT: In breast cancer, the expression of CD24 represents a poorly recognised unfavourable prognostic factor. CD24 has been described to be potentially down-regulated by estrogen receptor alpha (ER). The present study was aimed at examining the predictive value of CD24 expression in tamoxifen-treated breast cancer cases. Sixty patients with primary invasive ductal breast cancers with post-operative tamoxifen treatment were enrolled in the study. Immmunohistochemical reactions were performed using monoclonal antibodies directed against CD24 and ER. Cases demonstrating cytoplasmic-membranous expression of CD24 (CD24c-m) proved to be characterised by a significantly lower expression of ER as compared to CD24c-m-negative cases. A multivariate progression analysis based on the Cox proportional hazard model demonstrated that CD24c-m expression is an independent prognostic factor for poor overall survival. The data from the present study suggested that CD24c-m expression is specific for tamoxifen-resistant breast cancer cases. CD24 should be subjected to comprehensive studies as a marker of resistance to tamoxifen treatment.
    Anticancer research 26(1B):629-34. · 1.73 Impact Factor
Browse more researchers